Sublingual immunotherapy and omalizumab cured allergic chronic rhinosinusitis and asthma: coincidence or synergistic effect?

Ann Allergy Asthma Immunol. 2019 Nov;123(5):440-443. doi: 10.1016/j.anai.2019.08.010. Epub 2019 Aug 21.

Authors

George N Konstantinou¹, Elisavet Kaitalidou², Nikolaos Skoulikaris³

Affiliations

¹ Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece. Electronic address: gnkonstantinou@gmail.com.
² Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece.
³ Department of Radiology, 424 General Military Training Hospital, Thessaloniki, Greece.

PMID: 31445089
DOI: 10.1016/j.anai.2019.08.010

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Anti-Allergic Agents / administration & dosage*
Anti-Asthmatic Agents / administration & dosage*
Asthma / therapy*
Chronic Disease
Combined Modality Therapy
Humans
Male
Nasal Polyps / therapy*
Omalizumab / administration & dosage*
Rhinitis, Allergic / therapy*
Sinusitis / therapy*
Sublingual Immunotherapy*
Young Adult

Substances

Anti-Allergic Agents
Anti-Asthmatic Agents
Omalizumab